(Open access funding provided by Semmelweis University)
Szakterületek:
Onkológia
Purpose of reviewAs the incidence of cutaneous melanoma continues to rise worldwide,
its heterogeneous presentation proves challenging for managing and preventing relapse.Recent
findingsWhile surgery remains a mainstay in staging and treatment of locoregional
metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable
in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory
mechanisms.SummaryIn this review, we will provide an overview of intralesional therapies
for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future
uses. We then discuss the landscape of current and emerging intralesional therapies.
